Patents Assigned to Aurelium BioPharma, Inc.
-
Patent number: 7670604Abstract: Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic agents.Type: GrantFiled: July 1, 2005Date of Patent: March 2, 2010Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Patent number: 7662580Abstract: Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.Type: GrantFiled: November 9, 2006Date of Patent: February 16, 2010Assignee: Aurelium BioPharma Inc.Inventors: Elias Georges, Julie Lanthier, Claudia Boucher, Anne-Marie Bonneau
-
Patent number: 7550256Abstract: Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.Type: GrantFiled: December 15, 2003Date of Patent: June 23, 2009Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Publication number: 20090004102Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.Type: ApplicationFiled: May 9, 2007Publication date: January 1, 2009Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Anne-Marie Bonneau, Frederic Dallaire, Lucile Serfass
-
Patent number: 7413851Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) protein on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin protein on the surface of a normal cell.Type: GrantFiled: December 15, 2003Date of Patent: August 19, 2008Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Patent number: 7358042Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell.Type: GrantFiled: March 15, 2004Date of Patent: April 15, 2008Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Publication number: 20070134687Abstract: Disclosed are methods for diagnosing cancer in a cell sample by detecting an increase in the levels of expression of marker genes in the cell sample as compared to the levels of expression of the same marker genes in a normal, nonneoplastic cell of the same tissue type. Also disclosed is a focused microarray device for diagnosis of cancer in a cell sample.Type: ApplicationFiled: September 12, 2006Publication date: June 14, 2007Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Claudia Boucher, Anne-Marie Bonneau
-
Patent number: 7226748Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.Type: GrantFiled: December 15, 2003Date of Patent: June 5, 2007Assignee: Aurelium BioPharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Publication number: 20070122830Abstract: Disclosed are methods for treating neoplastic cells, including reversing or preventing chemotherapeutic drug resistance, by increasing the sensitivity of the neoplastic cells to a chemotherapeutic drug. In addition, methods are further disclosed for diagnosing chemotherapeutic drug resistance in neoplastic cells by detecting an increase in the expression of prohibitin in such neoplastic cells as compared to the level of expression of prohibitin protein in a non-MDR neoplastic cell.Type: ApplicationFiled: November 9, 2006Publication date: May 31, 2007Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Panagiotis Prinos
-
Publication number: 20070122414Abstract: Disclosed are methods for treating and/or preventing neoplasms in a patient by contacting the neoplasm with therapeutic agents capable of binding, hybridizing, or interacting with proteins on the cell surface of neoplastic cells. In addition, therapeutic compositions are disclosed for the treatment and/or prevention of a neoplasm in a patient in need thereof.Type: ApplicationFiled: November 9, 2006Publication date: May 31, 2007Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Anne-Marie Bonneau
-
Publication number: 20070122856Abstract: Disclosed are methods for diagnosing ovarian cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic ovarian cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.Type: ApplicationFiled: November 9, 2006Publication date: May 31, 2007Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Julie Lanthier, Claudia Boucher, Anne-Marie Bonneau
-
Publication number: 20070111244Abstract: Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.Type: ApplicationFiled: November 9, 2006Publication date: May 17, 2007Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Julie Lanthier, Claudia Boucher, Anne-Marie Bonneau
-
Publication number: 20070077583Abstract: Disclosed are methods for detecting a neoplasm and/or chemotherapeutic drug resistance or angiogenic potential in neoplastic cells by detecting an increase in the expression of ?-enolase in such cells, or in the case of metastatic potential on the surface of such cells, as compared to the level of expression of ?-enolase protein in a normal or non-MDR neoplastic cell or on the surface of a non-metastatic neoplastic cell. In addition, methods and a composition are disclosed for increasing the sensitivity of a neoplasm to a chemotherapeutic drug treatment regime, for inhibiting angiogenesis and metastatic potential in chemotherapeutic drug resistant or neoplastic cells, and for inducing apoptosis in chemotherapeutic drug resistant or neoplastic cells.Type: ApplicationFiled: September 21, 2006Publication date: April 5, 2007Applicant: Aurelium BioPharma, Inc.Inventors: Elias Georges, Panagiotis Prinos
-
Publication number: 20040259112Abstract: Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.Type: ApplicationFiled: December 15, 2003Publication date: December 23, 2004Applicant: Aurelium BioPharma Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frederic Dallaire
-
Publication number: 20040185511Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.Type: ApplicationFiled: December 15, 2003Publication date: September 23, 2004Applicant: Aurelium BioPharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frederic Dallaire